Loading…
← CockpitCompetitor Analysis › 000739.SZ Apeloa Pharmaceutical Co. Ltd. Class AOpen in the cockpit ↗

Apeloa Pharmaceutical Co. Ltd. Class A000739.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese maker of active pharmaceutical ingredients (APIs), generic formulations and CDMO (contract manufacturing) services.

≈ A smaller Chinese Lonza/Cambrex (API/CDMO)Momentum leader 85
Mkt cap
$3.37B
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$40.6M
20-day average traded
Fwd P/E
22.9×
forward earnings
ROIC−WACC
+10.9 pp
WACC 6.6%
Hurdle
+0 pp
Req g minus delivered
Next earnings
107 days
5 Mar 2027
Close · CNYCN¥19.48
1D-1.7%
1W-4.1%
1M-10.3%
3M-14.6%
6M+17.4%
YTD+19.7%
1Y+29.7%
ATR %5.7%
52w lowhigh31.6% off high

What Apeloa Pharmaceutical does

Chinese maker of active pharmaceutical ingredients (APIs), generic formulations and CDMO (contract manufacturing) services.

Earns from three lines that behave differently: active ingredients sold in bulk to drug makers at prices that follow supply and demand, CDMO fees for developing or making medicines to other companies' specifications under contract, and generic drugs sold at home. Exports to regulated markets rely on its plants passing FDA and European inspections.

In one line: A smaller Chinese Lonza/Cambrex (API/CDMO).

Products and services

  • Active pharmaceutical ingredients (APIs)
  • CDMO contract manufacturing
  • Generic formulations

Customers

  • Global and domestic pharma companies (CDMO clients
  • Hospitals/pharmacies (own generics)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • API manufacturing + CDMO + generics

What could go right

  • Global API/CDMO outsourcing growth

What could go wrong

  • API price competition
  • Regulatory (FDA) inspection risk

Moat: narrow (scale, regulatory licence). FDA/EU-compliant API manufacturing facilities and scale versus smaller API makers.

Headquarters: Hengdian, Zhejiang, China · Employees: 6,787

Named competitors

Apeloa Pharmaceutical at a glance

Size Apeloa Pharmaceutical (000739.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.37B, the 722nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.48 on 18 Nov 2026.

Performance Over six months the shares gained 17.4%, against +3.4% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue fell 15.5% over the last twelve months (peer median +10.3%); the operating margin is 10.1% (peer median 12.7%).

Valuation It trades at 22.9× forward earnings against a peer median of 19.6× (6th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 10.9 points above its cost of capital (6.6% WACC).

Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026000739.SZ 117Peer median 104
Six months, rebased to 100: Apeloa Pharmaceutical against the median of its 20 peers (local-currency closes).

Apeloa Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥8.85BCN¥9.76BCN¥12.0BCN¥11.4BCN¥10.5B
Revenue growth—-19%+5%+9%—
Gross profitCN¥2.91BCN¥2.37BCN¥2.68BCN¥2.73BCN¥2.34B
EBITDAn/aCN¥1.56BCN¥1.61BCN¥1.64BCN¥1.30B
Net incomeCN¥804MCN¥891MCN¥1.03BCN¥1.06BCN¥989M
Free cash flowCN¥679MCN¥844MCN¥768MCN¥401MCN¥817M
Capital expenditureCN¥442MCN¥386MCN¥461MCN¥630MCN¥509M
Total debtCN¥3.00BCN¥3.41BCN¥3.01BCN¥3.43BCN¥3.70B

Quarterly statements and history in the cockpit →

Apeloa Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%+50%PPLPHARMAVKTX2096VRDNAMLX002262688180ARQTACUTAASSFZNWOCKPHARMA600535600521688266LEGNSLS000739.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Apeloa Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×PPLPHARMA2096002262600511ARQTACUTAASSFZN3320688266LEGN000739.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Apeloa Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%2096002262ARQTWOCKPHARMA688266000739.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Apeloa Pharmaceutical is the large dot.

Apeloa Pharmaceutical competitors and peer comparison

Head to head with its named competitors (000739.SZ vs 600521.SS vs 300363.SZ vs 002001.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Apeloa Pharmaceutical 000739.SZ$3.37B+17%-16%10%22.9×4.7%
Zhejiang Huahai Pharmaceutical 600521.SS$3.61B0%+10%12%20.1×6.4%
Porton Pharma Solutions 300363.SZ$1.66B+37%+6%-2%n/a2.1%
Zhejiang NHU 002001.SZ$11.8B-22%+11%33%9.7×-8.3%
Zhejiang Medicine 600216.SS$1.51B-26%-6%7%11.5×-7.8%
Zhejiang Xianju Pharmaceutical 002332.SZ$1.28B-1%+8%11%17.7×-0.4%
Zhejiang Hisun Pharmaceutical 600267.SS$2.19B+14%-7%15%15.0×-9.7%

How Apeloa Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Apeloa Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure000739.SZPeer medianRank in peer set
1-month return-10.3%-0.2%5th lowest of 21
6-month return+17.4%+3.4%8th highest of 20
Distance from 52-week high-31.6%-18.6%7th lowest of 21
Revenue growth (TTM)-15.5%+10.3%2nd lowest of 18
Operating margin10.1%12.7%8th lowest of 17
Forward P/E22.9×19.6×6th most expensive of 14
Growth the price implies (Req g, 7 yrs)4.7%-2.8%5th most demanding of 11
Growth delivered (Del g)+4.5%+6.9%4th lowest of 11
Hurdle (Req g minus delivered)+0.2 pp-13.3 pp4th most demanding of 11
ROIC minus cost of capital+10.9 pp+3.7 pp4th highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%n/an/an/a
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a

Questions

Who are Apeloa Pharmaceutical's main competitors?
Named competitors: Zhejiang Huahai Pharmaceutical (600521.SS), Porton Pharma Solutions (300363.SZ), Zhejiang NHU (002001.SZ), Zhejiang Medicine (600216.SS), Zhejiang Xianju Pharmaceutical (002332.SZ), Zhejiang Hisun Pharmaceutical (600267.SS). The cockpit's measured peer set (industry) also includes Piramal Pharma (PPLPHARMA.NS), Viking Therapeutics (VKTX), Simcere Pharmaceutical (2096.HK), Viridian Therapeutics (VRDN), Amylyx Pharmaceuticals (AMLX), Jiangsu Nhwa Pharmaceutical (002262.SZ).
Is Apeloa Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 22.9× against a peer median of 19.6×, 6th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Apeloa Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +17.4% against +3.4% for the median peer; over one year +29.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.